Novavax reports Q4 earnings on Thursday with analysts expecting a wider loss per share than last year. The vaccine maker is actively diversifying beyond its COVID-19 product, highlighted by a new license with Pfizer. While losses are projected to widen, investors are watching for potential oncology partnerships during the upcoming earnings call.